Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Evgenia Glogova"'
Autor:
Wieczorek, Holger N. Lode, Ruth Ladenstein, Sascha Troschke-Meurer, Linda Struppe, Nikolai Siebert, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Evgenia Glogova, Patrick Hundsdoerfer, Angelika Eggert, Anna Zaniewska-Tekieli, Walentyna Balwierz, Aleksandra
Publikováno v:
Cancers; Volume 15; Issue 13; Pages: 3364
The anti-disialoganglioside (GD2) monoclonal antibody dinutuximab beta is approved for the maintenance treatment of high-risk neuroblastoma. Dinutuximab beta combined with different chemotherapy regimens is being investigated in various clinical sett
Autor:
Anna Eichinger, Ulrike Poetschger, Evgenia Glogova, Peter Bader, Oliver Basu, Rita Beier, Birgit Burkhardt, Carl-Friedrich Classen, Alexander Claviez, Selim Corbacioglu, Hedwig E. Deubzer, Johann Greil, Bernd Gruhn, Tayfun Güngör, Kinan Kafa, Jörn-Sven Kühl, Peter Lang, Bjoern Soenke Lange, Roland Meisel, Ingo Müller, Martin G. Sauer, Paul-Gerhardt Schlegel, Ansgar Schulz, Daniel Stachel, Brigitte Strahm, Angela Wawer, Christina Peters, Michael H. Albert
Publikováno v:
Leukemia. 36(11)
Total body irradiation (TBI)-based conditioning is associated with superior leukemia-free survival in children with ALL undergoing HSCT. However, the risk for subsequent malignant neoplasms (SMN) remains a significant concern. We analyzed 705 pediatr
Autor:
Peter Bader, Brigitte Strahm, Joannis Mytilineos, Lena Oevermann, Ulrike Pötschger, Martin Sauer, Cornelia Eckert, Florian Babor, Christina Peters, Roland Meisel, Martin Schrappe, Martin Zimmermann, Friedhelm R. Schuster, Nadine Scherenschlich, Bernd Gruhn, Bernhard Kremens, Tobias Feuchtinger, Markus Uhrberg, Gabriele Escherich, Wilhelm Wössmann, Martina Ahlmann, Peter Lang, Meinolf Siepermann, Daniel Stachel, Herbert Pichler, Arndt Borkhardt, Tayfun Güngör, Peter A. Horn, Evgenia Glogova, Markus Mezger, Angela R. Manser, Gunnar Cario, Ingo Müller
Publikováno v:
Bone Marrow Transplantation. 54:1847-1858
Although allogeneic hematopoietic stem-cell transplantation (HSCT) provides high cure rates for children with high-risk acute lymphoblastic leukaemia (ALL), relapses remain the main cause of treatment failure. Whereas donor killer cell immunoglobulin
Autor:
Martin Benesch, Reinhold Kerbl, Edit Bardi, Marlene Mayer, Agnes Gamper, Andrea Ziegler, Ruth Ladenstein, Stefan Fiedler, Georg Ebetsberger-Dachs, Gabriele Amann, Roman Crazzolara, Christian Urban, Evgenia Glogova, Peter F. Ambros, Neil Jones, Karin Dieckmann, Bernhard Meister, Bettina Brunner-Herglotz, Ernst Horcher, Inge M. Ambros
Publikováno v:
Cancers, Vol 13, Iss 572, p 572 (2021)
Cancers
Volume 13
Issue 3
Cancers
Volume 13
Issue 3
We evaluated long-term outcome and genomic profiles in the Austrian Neuroblastoma Trial A-NB94 which applied a risk-adapted strategy of treatment (RAST) using stage, age and MYCN amplification (MNA) status for stratification. RAST ranged from surgery
Autor:
Anna Eichinger, Evgenia Glogova, Ulrike Poetschger, Peter Bader, Oliver Basu, Rita Beier, Birgit Burkhardt, Carl-Friedrich Classen, Alexander Claviez, Selim Corbacioglu, Hedwig Deubzer, Johann Greil, Bernd Gruhn, Tayfun Gungor, Kinan Kafa, Peter Lang, Bjoern Soenke Lange, Ingo Mueller, Martin G. Sauer, Paul-Gerhard Schlegel, Ansgar Schulz, Klaus Daniel Stachel, Brigitte R. Strahm, Angela Wawer, Jörn-Sven Kühl, Roland Meisel, Christina Peters, Michael H. Albert
Publikováno v:
Transplantation and Cellular Therapy. 28:S79
Autor:
Taifun Gungor, Marc Bierings, Jean Hugues Dalle, Marianne Ifversen, Ulrike Poetschger, Christina Peters, Petr Sedlacek, Isaac Yaniv, Adriana Balduzzi, Anna Pieczonka, Arjan C. Lankester, Evgenia Glogova, Jacek Wachowiak, Peter Bader, Peter Svec, Akif Yeşilipek, Jacek Toporski
Publikováno v:
Bone Marrow Transplantation
Bone Marrow Transplantation, 56, 257-266. NATURE PUBLISHING GROUP
Bone Marrow Transplantation, 56, 257-266. NATURE PUBLISHING GROUP
Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two consecutive international prospective studies, ALL-SCT-(I)BFM 2003 and 2007 were conducted in 1150 pediatric patients. 569 presented with VHR disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38d16c6592302d5927a39c0a8c76c134
https://doi.org/10.1038/s41409-020-01014-x
https://doi.org/10.1038/s41409-020-01014-x
Autor:
Lucia Di Maio, Arjan C. Lankester, Sabina Sufliarska, Akif Yesilipek, Petr Sedlacek, Marianne Ifversen, Jacek Toporski, Krzysztof Kałwak, Isaac Yaniv, Adriana Balduzzi, Christina Peters, Jacek Wachowiak, Ulrike Poetschger, Evgenia Glogova, Jean Hugues Dalle, Marc Bierings
Publikováno v:
Biology of Blood and Marrow Transplantation, 25(11), 2197-2210. ELSEVIER SCIENCE INC
Eligibility criteria for hematopoietic stem cell transplantation (HSCT) in acute lymphoblastic leukemia (ALL) vary according to disease characteristics, response to treatment, and type of available donor. As the risk profile of the patient worsens, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4e6bfe282728bdc95f501e9ce13da90
https://hdl.handle.net/1887/121741
https://hdl.handle.net/1887/121741
Autor:
Gernot Engstler, Volker Witt, Evgenia Glogova, Herbert Pichler, Susanne Karlhuber, Ulrike Poetschger, Susanne Matthes-Martin, Manuel Martin, Karolina Horner, Wolfgang Holter, Werner Eibler
Publikováno v:
Biology of Blood and Marrow Transplantation. 23:1128-1133
Veno-occlusive disease (VOD) remains a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Prophylactic use of defibrotide (DF) might further reduce VOD rates but has no impact on the incidence of severe VOD or VOD-a
Publikováno v:
The EBMT Handbook ISBN: 9783030022778
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f80404ba27a2cb293f0480abd65900f
http://hdl.handle.net/11392/2418194
http://hdl.handle.net/11392/2418194
Autor:
Ulrike Pötschger, Sabine Breuer, Thomas Lion, Herbert Pichler, Margit König, Susanne Karlhuber, Oskar A. Haas, Gerhard Fritsch, Susanne Matthes-Martin, H Daxberger, Anita Lawitschka, Ece D. Güclü, Wolfgang Holter, Evgenia Glogova
Publikováno v:
British Journal of Haematology. 173:905-917
The impact of persistent mixed chimerism (MC) after haematopoietic stem cell transplantation (HSCT) remains unclarified. We investigated the incidence of MC in peripheral blood beyond day +50 after HSCT and its impact on rejection, chronic graft-vers